Hillevax, INC

HilleVax, Inc. has completed its acquisition by XOMA Royalty Corporation for $1.95 cash plus a contingent value right per share, leading to its delisting from Nasdaq.

HilleVax, Inc. reported its second quarter 2025 financial results, alongside the announcement of a definitive merger agreement to be acquired by XOMA Royalty Corporation for $1.95 per share plus a contingent value right.

HilleVax, a clinical-stage biopharmaceutical company, has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $1.95 per share in cash plus a contingent value right.

HilleVax, Inc. announced the successful election of three Class III directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm for fiscal year 2025 at its Annual Meeting of Stockholders held on June 23, 2025.

HilleVax reported its Q1 2025 financial results, showing a reduced net loss and lower operating expenses, while also exploring strategic alternatives for its norovirus vaccine candidates.

HilleVax reports its full year 2024 financial results, highlighting $171.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and exploring strategic alternatives for its norovirus vaccine candidates.

HilleVax reports significantly reduced net losses in Q2 2025, driven by cost cuts and the discontinuation of its lead vaccine candidate, as it moves towards acquisition by XOMA.

HilleVax, Inc. reports a significantly reduced net loss for Q1 2025 compared to Q1 2024, primarily due to decreased research and development expenses following the discontinuation of HIL-214 development in infants.

HilleVax discontinues development of its lead vaccine candidate, HIL-214, after a Phase 2b trial failed to meet its primary endpoint, and announces workforce reductions.

HilleVax's Phase 2b trial for its norovirus vaccine candidate, HIL-214, failed to meet its primary endpoint, leading to a workforce reduction and strategic shift.

HilleVax reported a net loss of $46.8 million for the first quarter of 2024, while advancing its norovirus vaccine candidate, HIL-214, and acquiring rights to a new vaccine candidate, HIL-216.

HilleVax's Phase 2b trial for its norovirus vaccine candidate failed to meet its primary endpoint, leading to a strategic shift and workforce reduction.

HilleVax's 10-K filing details their progress in developing a norovirus vaccine, HIL-214, and their financial status as a clinical-stage biopharmaceutical company.

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. have sold their entire 6,724,000 shares of HilleVax, Inc. common stock for $1.95 per share as part of a tender offer by XOMA Royalty Corporation.

Frazier Life Sciences X, L.P. and Patrick J. Heron disposed of HilleVax, Inc. common stock and restricted stock units following the company's merger with XRA 4 Corp. for $1.95 cash and a CVR per share.

HilleVax, Inc. President and CEO, Robert Hershberg, reported the disposition of all his common stock holdings following the company's acquisition by XOMA Royalty Corporation.

HilleVax Director Nanette Cocero reported the disposition of common stock and vested RSUs following the company's merger with XOMA Royalty Corporation.

HilleVax, Inc. became a wholly-owned subsidiary of XOMA Royalty Corporation following a tender offer and merger, with shareholders receiving $1.95 cash and one CVR per share.

HilleVax Director Shelley Chu reported the disposition of 17,199 common shares following the company's merger with XOMA Royalty Corporation.

HilleVax, Inc. will hold its annual stockholders meeting on June 23, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent accounting firm.

HilleVax, Inc. will hold its annual meeting of stockholders virtually on June 23, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm.

HilleVax, Inc. will hold its annual meeting of stockholders on June 6, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and approve an amendment to the company's certificate of incorporation.

HilleVax, Inc. will hold its annual meeting of stockholders virtually on June 6, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and approve an amendment to the company's certificate of incorporation.

HilleVax, Inc. completed its merger with XOMA Royalty Corporation, resulting in the cancellation of all HilleVax common stock and Tang Capital ceasing to be a beneficial owner.

Hillevax, Inc. has completed its merger with XOMA Royalty Corporation, ceasing to be a publicly traded company.

Frazier Life Sciences and related entities cease beneficial ownership of HILLEVax common stock following its acquisition by XOMA Royalty Corporation.

Tang Capital Management, Kevin Tang, and affiliated entities have filed a Schedule 13D, disclosing a beneficial ownership of 9.8% of HilleVax, Inc.'s common stock, acquired for investment purposes.

EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported beneficial ownership of 5.8% of HilleVax, Inc.'s common stock.